15 Facts About Amantadine

Amantadine, sold under the brand name Gocovri among others, is a medication used to treat dyskinesia associated with parkinsonism and influenza caused by type A influenzavirus, though its use for the latter is no longer recommended due to widespread drug resistance.

Amantadine was first used for the treatment of influenza A After antiviral properties were initially reported in 1963, amantadine received approval for prophylaxis against the influenza virus A in 1976.

Amantadine is contraindicated in persons with end stage kidney disease, given that the drug is cleared by the kidneys.

Amantadine is the organic compound 1-adamantylamine or 1-aminoadamantane, which consists of an adamantane backbone with an amino group substituted at one of the four methyne positions.

Amantadine is a weak antagonist of the NMDA-type glutamate receptor, increases dopamine release, and blocks dopamine reuptake.

Related searches

Amantadine is used to treat Parkinson's disease-related dyskinesia and drug-induced parkinsonism syndromes.

Amantadine is not recommended for treatment or prophylaxis of influenza A in the United States.

Amantadine has no effect preventing or treating influenza B infections.

Amantadine has been shown to increase the rate of emergence from a MCS, defined by consistent demonstration of interactive communication and functional objective use.

Amantadine is generally well tolerated and has a mild side-effect profile.

Amantadine is Food and Drug Administration category C for pregnancy.

Amantadine is contraindicated in persons with end stage kidney disease.

Amantadine received approval for the treatment of influenza virus A in adults in 1976.

Amantadine was approved by the U S Food and Drug Administration in October 1968, as a prophylactic agent against Asian influenza and received approval for prophylactic use for influenza A in 1976.

Amantadine's reported that her symptoms worsened after she finished the course of amantadine.